(Q43854247)

27 November 2017

0 references

The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis (English)

1 reference

27 November 2017

1 reference

1

Darryl C Zeldin

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

27 November 2017

published in

1 reference

27 November 2017

volume

165

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

146-147

1 reference

Allergic lung responses are increased in prostaglandin H synthase-deficient mice.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

Treatment of asthma with drugs modifying the leukotriene pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

Protection from pulmonary fibrosis in leukotriene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.165.2.2111077B

10.1164/AJRCCM.165.2.2111077B

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference